VANGUARD GROUP INC 13D and 13G filings for Protagonist Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-27 11:33 am Sale | 2026-03-13 | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | VANGUARD GROUP INC | 0 0.000% | -5,413,690 (Position Closed) | Filing |
| 2026-01-30 2:43 pm Purchase | 2025-12-31 | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | VANGUARD GROUP INC | 5,413,690 8.650% | 1,197,609 (+28.41%) | Filing |
| 2024-11-12 4:51 pm Unchanged | 2024-09-30 | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | VANGUARD GROUP INC | 4,216,081 7.150% | 0 (Unchanged) | Filing |
| 2024-11-04 1:22 pm Purchase | 2024-09-30 | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | VANGUARD GROUP INC | 4,216,081 7.150% | 1,062,165 (+33.68%) | Filing |
| 2024-02-13 5:12 pm Purchase | 2023-12-29 | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | VANGUARD GROUP INC | 3,153,916 5.470% | 56,202 (+1.81%) | Filing |
| 2023-02-09 11:30 am Purchase | 2022-12-30 | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | VANGUARD GROUP INC | 3,097,714 6.300% | 3,097,714 (New Position) | Filing |